Twist Bioscience (NASDAQ:TWST) CEO Sells 655 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 655 shares of Twist Bioscience stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $200.00, for a total value of $131,000.00. Following the completion of the sale, the chief executive officer owned 613,044 shares in the company, valued at approximately $122,608,800. The trade was a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Up 8.7%

TWST stock traded up $16.33 during midday trading on Monday, hitting $205.00. The company’s stock had a trading volume of 3,204,075 shares, compared to its average volume of 1,622,926. The firm has a 50-day simple moving average of $136.40 and a 200-day simple moving average of $92.42. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $12.86 billion, a P/E ratio of -92.34 and a beta of 2.19. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $207.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.33 EPS. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Barclays upped their target price on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a research note on Monday, July 6th. Robert W. Baird upped their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, BWS Financial restated a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a research note on Friday, September 18th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $115.27.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the business. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the 1st quarter worth $31,000. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter worth approximately $33,000. Strategic Advocates LLC boosted its position in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Twist Bioscience by 89.7% in the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period. Finally, Fifth Third Bancorp acquired a new position in shares of Twist Bioscience during the first quarter worth about $54,000.

Twist Bioscience News Roundup

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
• Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
• Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
• Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
• Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.